Effect of Perioperative Supplementation with Arginine and Omega-3 on Postoperative Complications in Patients Undergoing Gastrointestinal Cancer Surgery: A Pilot Open-Label Randomized Controlled Trial

Basit Öğe Kaydı
dc.contributor.authorSakhri, Saida
dc.contributor.authorOthman, Rym Ben
dc.contributor.authorJerbi, Chaima
dc.contributor.authorCeylan, Halil Ibrahim
dc.contributor.authorNaija, Lamia
dc.contributor.authorZemni, Ines
dc.contributor.authorDergaa, Ismail
dc.date.accessioned2026-09-01T15:52:33Z
dc.date.available2026-09-01T15:52:33Z
dc.date.issued2026
dc.departmentBayburt Üniversitesi
dc.description.abstractBackground: Perioperative immunonutrition, including arginine and omega-3 fatty acids, has been proposed to support postoperative recovery by modulating immune function. Aim: To evaluate the effects of perioperative arginine and omega-3 supplementation on postoperative infectious complications, mortality, hospital length of stay, intensive care unit duration, and inflammatory markers in patients undergoing gastrointestinal cancer surgery. Methods: In this Pilot Open-Label randomized trial, 35 adult patients scheduled for elective gastrointestinal cancer surgery at Salah Azaiez Institute were randomly assigned to receive either perioperative immunonutrition (n = 18; three daily capsules of omega-3 and one sachet of Arginine+ for 7 days preoperatively and 7 days postoperatively) or standard care (n = 17). Primary endpoints were postoperative infectious complications and 1-month mortality. Secondary endpoints included hospital length of stay, ICU duration, and postoperative biochemical markers. Results: No statistically significant differences were observed between groups in 1-month mortality (p = 0.324), hospital length of stay (median 7 vs. 7 days, p = 0.392), or ICU duration (median 5 vs. 6 days, p = 0.601). Urinary tract infection (5.9% vs. 11.1%, p = 0.939) and wound infection rates (5.9% vs. 11.1%, p = 0.581) were comparable. Importantly, postoperative C-reactive protein and other inflammatory markers did not differ significantly between groups (CRP: 165 vs. 175 mg/L; intergroup p = 0.798). Conclusions: In this trial, perioperative immunonutrition with arginine and omega-3 fatty acids did not improve postoperative clinical outcomes or inflammatory markers in patients undergoing gastrointestinal cancer surgery. At the administered dose and within a small, heterogeneous cohort, immunonutrition did not provide additional benefit beyond standard care. Larger, adequately powered multicenter trials with optimized dosing are required to clarify its role in gastrointestinal oncology.
dc.identifier.doi10.3390/nu18040651
dc.identifier.issn2072-6643
dc.identifier.issue4
dc.identifier.pmid41754168
dc.identifier.scopus2-s2.0-105031220022
dc.identifier.scopusqualityN/A
dc.identifier.urihttp://dx.doi.org/10.3390/nu18040651
dc.identifier.urihttps://hdl.handle.net/20.500.12403/8441
dc.identifier.volume18
dc.identifier.wosWOS:001701062000001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMDPI
dc.relation.ispartofNutrients
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260820
dc.subjectComplications
dc.subjectGastrointestinal Cancer
dc.subjectImmunonutrition
dc.subjectOncological Surgery
dc.subjectPostoperative Outcomes
dc.subjectSurgical Complications
dc.subjectSurgical Site Infections
dc.subjectWound Infections
dc.titleEffect of Perioperative Supplementation with Arginine and Omega-3 on Postoperative Complications in Patients Undergoing Gastrointestinal Cancer Surgery: A Pilot Open-Label Randomized Controlled Trial
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu